0001179110-17-010441.txt : 20170718
0001179110-17-010441.hdr.sgml : 20170718
20170718210325
ACCESSION NUMBER: 0001179110-17-010441
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170714
FILED AS OF DATE: 20170718
DATE AS OF CHANGE: 20170718
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HBM Healthcare Investments (Cayman) Ltd.
CENTRAL INDEX KEY: 0001232258
STATE OF INCORPORATION: E9
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38132
FILM NUMBER: 17970518
BUSINESS ADDRESS:
STREET 1: 2454 WEST BAY ROAD, 3RD FLOOR
CITY: GRAND CAYMAN
STATE: E9
ZIP: 00000
BUSINESS PHONE: 1 345 946 8002
MAIL ADDRESS:
STREET 1: P.O BOX 30852
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-1204
FORMER NAME:
FORMER CONFORMED NAME: HBM BIOVENTURES CAYMAN LTD
DATE OF NAME CHANGE: 20030512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics Plc
CENTRAL INDEX KEY: 0001703287
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: 6108166640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Plc
DATE OF NAME CHANGE: 20170407
4
1
edgar.xml
FORM 4 -
X0306
4
2017-07-14
0
0001703287
Nabriva Therapeutics Plc
NBRV
0001232258
HBM Healthcare Investments (Cayman) Ltd.
GOVERNORS SQUARE, SUITE #4-212-2
23 LIME TREE BAY AVE., WEST BAY
GRAND CAYMAN
E9
00000
CAYMAN ISLANDS
0
0
1
0
Ordinary Shares
2017-07-14
4
S
0
21055
10.5338
D
2490952
D
Ordinary Shares
2017-07-17
4
S
0
47460
10.5018
D
2443492
D
Ordinary Shares
2017-07-18
4
S
0
1339
10.50
D
2442153
D
The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $10.50 to $10.64. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $10.50 to $10.64. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.
/s/ Jean-Marc Lesieur, Director
2017-07-18